$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2024 Q1 Form 10-K Financial Statement

#000141057824000385 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.513M $3.106M $10.69M
YoY Change -32.06% 26.06% -1.59%
% of Gross Profit
Research & Development $961.0K $1.698M $10.75M
YoY Change -67.13% -30.72% -23.0%
% of Gross Profit
Depreciation & Amortization $64.00K $65.00K $265.0K
YoY Change -4.48% -7.14% -7.02%
% of Gross Profit
Operating Expenses $961.0K $4.804M $10.75M
YoY Change -67.13% -2.26% -23.0%
Operating Profit -$2.474M -$21.44M
YoY Change -51.97% -13.63%
Interest Expense -$940.0K -$236.0K $4.694M
YoY Change
% of Operating Profit
Other Income/Expense, Net $13.00K -$538.0K -$447.0K
YoY Change -85.87% 422.33% -182.02%
Pretax Income -$3.401M -$5.578M -$17.19M
YoY Change -32.77% 11.16% -29.18%
Income Tax
% Of Pretax Income
Net Earnings -$3.401M -$5.578M -$17.19M
YoY Change -32.77% 11.16% -29.18%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05 -$0.40
Diluted Earnings Per Share -$0.05 -$0.11 -$0.40
COMMON SHARES
Basic Shares Outstanding 68.34M 48.98M 43.08M
Diluted Shares Outstanding 64.74M 43.08M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $779.0K $1.300M $1.300M
YoY Change -65.02% -56.42% -56.42%
Cash & Equivalents $779.0K $1.300M $1.300M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $454.0K $548.0K $548.0K
YoY Change -31.0% 1612.5% 1612.5%
Inventory
Prepaid Expenses
Receivables $26.00K $51.00K $51.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.259M $1.899M $1.899M
YoY Change -57.02% -38.86% -38.86%
LONG-TERM ASSETS
Property, Plant & Equipment $622.0K $686.0K $2.102M
YoY Change -28.18% -26.47% -60.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.089M $2.309M $207.0K
YoY Change -57.74% -56.8% 800.0%
Total Long-Term Assets $2.089M $2.309M $2.309M
YoY Change -57.74% -56.8% -56.8%
TOTAL ASSETS
Total Short-Term Assets $1.259M $1.899M $1.899M
Total Long-Term Assets $2.089M $2.309M $2.309M
Total Assets $3.348M $4.208M $4.208M
YoY Change -57.47% -50.21% -50.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.690M $4.954M $4.954M
YoY Change -39.89% -20.4% -20.4%
Accrued Expenses $636.0K $1.240M $1.843M
YoY Change 271.93% 1376.19% 21.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.831M $7.800M $7.800M
YoY Change -34.46% -11.36% -11.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.067M $1.266M $1.266M
YoY Change -9.74% -52.51% -52.51%
Total Long-Term Liabilities $2.067M $1.266M $1.266M
YoY Change -9.74% -52.51% -52.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.831M $7.800M $7.800M
Total Long-Term Liabilities $2.067M $1.266M $1.266M
Total Liabilities $8.898M $9.066M $9.066M
YoY Change -30.0% -20.93% -20.93%
SHAREHOLDERS EQUITY
Retained Earnings -$218.0M -$215.0M
YoY Change 7.45% 8.59%
Common Stock $213.0M $210.3M
YoY Change 7.48% 7.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.550M -$4.858M -$4.858M
YoY Change
Total Liabilities & Shareholders Equity $3.348M $4.208M $4.208M
YoY Change -57.47% -50.21% -50.21%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$3.401M -$5.578M -$17.19M
YoY Change -32.77% 11.16% -29.18%
Depreciation, Depletion And Amortization $64.00K $65.00K $265.0K
YoY Change -4.48% -7.14% -7.02%
Cash From Operating Activities -$3.063M -$3.288M -$20.46M
YoY Change -23.16% -29.26% 5.89%
INVESTING ACTIVITIES
Capital Expenditures -$2.000K $18.00K
YoY Change -37.93%
Acquisitions
YoY Change
Other Investing Activities $0.00 $191.0K $2.211M
YoY Change -100.0% -81.6% 115.29%
Cash From Investing Activities $0.00 $193.0K $2.193M
YoY Change -100.0% -81.41% 119.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $171.0K
YoY Change 13.25%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.539M 3.348M 18.98M
YoY Change -21.39% 1306.72% 7873.95%
NET CHANGE
Cash From Operating Activities -3.063M -3.288M -20.46M
Cash From Investing Activities 0.000 193.0K 2.193M
Cash From Financing Activities 2.539M 3.348M 18.98M
Net Change In Cash -524.0K 253.0K 713.0K
YoY Change -141.95% -107.5% -103.94%
FREE CASH FLOW
Cash From Operating Activities -$3.063M -$3.288M -$20.46M
Capital Expenditures -$2.000K $18.00K
Free Cash Flow -$3.286M -$20.48M
YoY Change -29.3% 5.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43075938
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36509060
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001137883
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60489208
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36694078
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215013000
CY2023 bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-36641
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6224000
CY2023 dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
CY2023 dei City Area Code
CityAreaCode
201
CY2023 dei Local Phone Number
LocalPhoneNumber
488-0460
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
CY2023 dei Trading Symbol
TradingSymbol
BCLI
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
78886897
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
68341857
CY2023 dei Auditor Name
AuditorName
Brightman Almagor Zohar & Co.
CY2023 dei Auditor Location
AuditorLocation
Tel Aviv, Israel
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1300000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
772000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
2211000
CY2023Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
51000
CY2022Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
91000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
548000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1899000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3106000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
22000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
23000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
185000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1416000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4389000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
686000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
933000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2309000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5345000
CY2023Q4 us-gaap Assets
Assets
4208000
CY2022Q4 us-gaap Assets
Assets
8451000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4954000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1240000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19342000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1682000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
84000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
603000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1427000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1003000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1065000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7800000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8800000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
672000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2666000
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
594000
CY2022Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
0
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1266000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2666000
CY2023Q4 us-gaap Liabilities
Liabilities
9066000
CY2022Q4 us-gaap Liabilities
Liabilities
11466000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60489208
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36694078
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
210258000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
194910000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215013000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197821000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4858000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4208000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8451000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10746000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13956000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10693000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10866000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-21439000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-24822000
CY2023 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
447000
CY2022 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-545000
CY2023 bcli Fair Value Adjustments Of Warrants And Stock Issuance Costs
FairValueAdjustmentsOfWarrantsAndStockIssuanceCosts
-4694000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-17192000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24277000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43075938
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36509060
CY2022 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
238000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24277000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1490000
CY2023 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
11881000
CY2023 bcli Issuance Of Shares For Private Placement Value
IssuanceOfSharesForPrivatePlacementValue
1978000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-17192000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4858000
CY2023 us-gaap Profit Loss
ProfitLoss
-17192000
CY2022 us-gaap Profit Loss
ProfitLoss
-24277000
CY2023 us-gaap Depreciation
Depreciation
265000
CY2022 us-gaap Depreciation
Depreciation
285000
CY2023 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1490000
CY2022 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1682000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
155000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-594000
CY2023 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
475000
CY2022 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-1067000
CY2023 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1270000
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2524000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4525000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1094000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-7000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20458000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19320000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000
CY2023 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-2211000
CY2022 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-1027000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2193000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
998000
CY2023 bcli Proceeds From At Market
ProceedsFromAtMarket
11881000
CY2022 bcli Proceeds From At Market
ProceedsFromAtMarket
238000
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7097000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18978000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
238000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
713000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18084000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
772000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18856000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1485000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
772000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1576000
CY2023 bcli Right Of Use Asset Decreased Resulted From Lease Modification
RightOfUseAssetDecreasedResultedFromLeaseModification
1695000
CY2023 bcli Lease Liability Decreased Resulted From Lease Modification
LeaseLiabilityDecreasedResultedFromLeaseModification
1395000
CY2023 bcli Lease Expense Resulted From Lease Modification
LeaseExpenseResultedFromLeaseModification
300000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2023Q4 bcli Percentage Of Targeted Reduction In Headcount
PercentageOfTargetedReductionInHeadcount
0.30
CY2023Q4 bcli Restructuring Percentage Of Reduction In Operating Expenses
RestructuringPercentageOfReductionInOperatingExpenses
0.50
CY2023 us-gaap Severance Costs1
SeveranceCosts1
910000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<table style="border-collapse:collapse;border:0;"><tr><td style="width:57.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Use of estimates:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 93.6pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect reported amounts and disclosures made. Actual results could differ from those estimates.</p>
CY2023 bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
CY2023 bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
CY2023 bcli Short Term Deposits Policy Policytextblock
ShortTermDepositsPolicyPolicytextblock
<table style="border-collapse:collapse;border:0;"><tr><td style="width:57.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">F.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Short-term deposits:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 93.6pt;"><span style="font-weight:normal;">Short-term deposits are deposits with an original maturity of more than three months from the date of investment and which do not meet the definition of cash equivalents.</span></p>
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.0833
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1416000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4389000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1275000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4093000
CY2023 us-gaap Lease Cost
LeaseCost
1467000
CY2022 us-gaap Lease Cost
LeaseCost
975000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
1313000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1538000
CY2023 bcli Operating Lease Expense Income
OperatingLeaseExpenseIncome
1321000
CY2022 bcli Operating Lease Expense Income
OperatingLeaseExpenseIncome
1514000
CY2023 bcli Finance Lease Expenses Income
FinanceLeaseExpensesIncome
146000
CY2022 bcli Finance Lease Expenses Income
FinanceLeaseExpensesIncome
-569000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M9D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0866
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
611000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
576000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
189000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1376000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
101000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1275000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3449000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3431000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2763000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2498000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
686000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
933000
CY2023 us-gaap Depreciation
Depreciation
265000
CY2022 us-gaap Depreciation
Depreciation
285000
CY2023 bcli Grants Underlying Basis
GrantsUnderlyingBasis
The grant is linked to the exchange rate of the dollar and bears interest of Libor per annum.
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
0
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
171000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.91
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.18
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.79
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.81
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0340
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0449
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0142
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0361
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1605783
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1510117
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y3M18D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y11M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1201133
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1152850
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1490000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1682000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17192000
CY2023Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
10746000
CY2022Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
14156000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10746000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13956000
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
182489000
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
155310000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
50788000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42683000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
50788000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42683000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
50788000
CY2023Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
182489000
CY2023Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
182489000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8837000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-9989000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-8355000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-14288000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24277000
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
1197

Files In Submission

Name View Source Status
0001410578-24-000385-index-headers.html Edgar Link pending
0001410578-24-000385-index.html Edgar Link pending
0001410578-24-000385.txt Edgar Link pending
0001410578-24-000385-xbrl.zip Edgar Link pending
bcli-20231231.xsd Edgar Link pending
bcli-20231231x10k.htm Edgar Link pending
bcli-20231231x10k001.jpg Edgar Link pending
bcli-20231231xex10d69.htm Edgar Link pending
bcli-20231231xex10d70.htm Edgar Link pending
bcli-20231231xex10d71.htm Edgar Link pending
bcli-20231231xex10d72.htm Edgar Link pending
bcli-20231231xex10d73.htm Edgar Link pending
bcli-20231231xex21.htm Edgar Link pending
bcli-20231231xex23d1.htm Edgar Link pending
bcli-20231231xex31d1.htm Edgar Link pending
bcli-20231231xex31d2.htm Edgar Link pending
bcli-20231231xex32d1.htm Edgar Link pending
bcli-20231231xex32d2.htm Edgar Link pending
bcli-20231231xex97d1.htm Edgar Link pending
bcli-20231231_cal.xml Edgar Link unprocessable
bcli-20231231_def.xml Edgar Link unprocessable
bcli-20231231_lab.xml Edgar Link unprocessable
bcli-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcli-20231231x10k_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending